IGF2BP3 and pancreatic adenocarcinoma: Although only stage 2 PAAD patients showed statistically significant differences in IGF2BP3 expression compared with healthy individuals, the median IGF2BP3 expression was higher in stage 2 to 4 patients than in healthy individuals.